This post was originally published on this site A record number of people are expected to travel this holiday season. The travelers will undoubtedly include familial caregivers journeying with loved ones who have dementia. These are courageous individuals, perhaps seeking one last hurrah before Alzheimer’s disease prevents them from traveling to faraway destinations. Taking a…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
Phase 1 Trial for Potential Alzheimer’s Therapy Yields Positive Results
This post was originally published on this site A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, “Phase 1 Study of NDX-1017: Safety, Pharmacokinetics and…
Dutch Researchers Develop Apps to Help Caregivers of Dementia Patients
This post was originally published on this site Researchers at Maastricht University Medical Center in the Netherlands have developed two online apps to improve the lives of people who care for dementia patients, and will soon create one for patients themselves. One app provides caregivers with information they can use to achieve balance in their lives. Those…
Nuplazid Lowers Dementia-related Psychosis Relapse Risk by Nearly 3 Times, HARMONY Study Shows
This post was originally published on this site People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase 3 trial were almost three times less likely to have a psychosis relapse — a worsening of delusions and hallucinations — than others, HARMONY trial data show. HARMONY met its main goal, significantly lowering the…
ADDF Awards $6M to Projects Looking to Better Diagnose Alzheimer’s, Dementia
This post was originally published on this site The Alzheimer’s Drug Discovery Foundation (ADDF) announced a second round of research awards totaling about $6 million, part of its Diagnostics Accelerator initiative into better diagnostics for Alzheimer’s (AD) and related dementia. These six global investigative efforts are in various stages of development, and include an advanced blood…
How to Prevent Alzheimer’s Patients from Wandering
This post was originally published on this site “All that is gold does not glitter / Not all those who wander are lost / The old that is strong does not wither / Deep roots are not reached by the frost.” — J.R.R.Tolkien Why do people with Alzheimer’s disease wander? The tendency to wander in…
Repeat Coding in Gene Region Linked to Risk of Late-onset Alzheimer’s, Study Suggests
This post was originally published on this site Longer sequence repeats in or near two genes may be linked to a higher risk of late-onset Alzheimer’s disease, a study reports. The study “Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene” was published…
First Patient Dosed in INmune Bio’s Phase1b Trial Testing XPro1595 Anti-inflammatory Compound for Alzheimer’s
This post was originally published on this site INmune Bio has dosed the first patient in its Phase 1b trial (NCT03943264) testing the safety and efficacy of its next-generation anti-inflammatory compound XPro1595 for Alzheimer’s disease (AD). The trial is currently recruiting in different sites across Australia. More information can be found here. Instead of targeting…
Trials into Possible Treatment for Agitation in Alzheimer’s Patients to Continue, Avanir Says
This post was originally published on this site A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a…
Bluefield Project to Cure Frontotemporal Dementia Gets $1.2M to Advance FTD Blood Testing
This post was originally published on this site The Bluefield Project to Cure FTD will receive $1.2 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to validate an exploratory blood test in frontotemporal dementia (FTD). The award is the first FTD investment through the foundation’s Diagnostics Accelerator, a venture philanthropy vehicle to advance the development of…
Phase 2/3 Trial of Oral Troriluzole in Easing Alzheimer’s Dementia Fully Enrolled
This post was originally published on this site Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow memory and…
Phase 2 Trial to Test New Way of Measuring Tau Plaques in Living Brains
This post was originally published on this site A newly opened Phase 2 clinical trial will test the sensitivity of new imaging tool for plaque buildup in the brains of people with mild cognitive impairment and dementia due to Alzheimer’s disease, Aprinoia Therapeutics announced. The trial is set to enroll 130 adults, 50 to 85 years…